TP53 and neoplasm: The recurrence observed in this case may be attributed to the aggressive nature of HER2 exon 20-mutant NSCLC, characterized by tumor heterogeneity and therapy resistance, compounded by co-occurring TP53 mutations contributing to genomic instability.